FDA Approves Lilly’s Osteoporosis Drug EVISTA(R) To Reduce The Risk Of Invasive Breast Cancer In Two Populations Of Postmenopausal Women

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved its osteoporosis drug EVISTA(R) (raloxifene HCl) for a new use to reduce the risk of invasive breast cancer in two populations: postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer. “The FDA’s decision marks a major milestone. [click link for full article]

More: continued here

Filed under: Breast Cancer on September 20th, 2007